A viable organ engineering pipeline requires the mass production of hundreds of billions of cells, tailorable and programmable cellular composition, and technologies to assemble these cells with perfusable vascular networks to support cell viability. Dr. Mark Skylar-Scott's lab is developing integrative technologies, including wetware, hardware, and software, to address cardiac tissue engineering at whole-organ scale.